Matches in SemOpenAlex for { <https://semopenalex.org/work/W4380085462> ?p ?o ?g. }
Showing items 1 to 69 of
69
with 100 items per page.
- W4380085462 endingPage "509" @default.
- W4380085462 startingPage "508" @default.
- W4380085462 abstract "Purpose: Extranodal NK/T-cell lymphoma (ENKTCL) is a highly aggressive lymphoma, with dismal outcomes for patients with advanced disease. No standard chemotherapy regimens were defined yet, especially for those with concurrent hemophagocytic lymphohistiocytosis (HLH). Methods: Patients with advanced stage ENKTCL were treated with combination of gemcitabine, pegaspargase, etoposide, and dexamethasone (GPED) since January 2020 in our center. The clinical characteristics, short-term efficacy, long-term survival outcomes, safety profiles, and potential prognostic biomarkers were analyzed. Results: Up to June 2022, a total of 20 patients with stage IV ENKTCL were treated with a median of four cycles of GPED regimen (range, 2–8). All patients had NRI score of 3 or more. Concurrent HLH were confirmed in 11 patients. The best responses to GPED regimen were complete remission (CR) in 40% of patients, partial remission (PR) in 45% of patients, rendering an overall response rate (ORR) of 85%. For the 11 patients with concurrent HLH, the CR rate was 36.4%, and the ORR was 72.8%. At a median follow-up time of 14.5 months (range, 2.1–28.4), nine patients had disease progression at a median of 6 months (3–21.6), and 5 patients died of ENKTCL. The predicted 1- and 2-year progression free survival (PFS) rate was 51% and 25%, respectively, and the overall survival (OS) rate was 72% and 54%, respectively. The major adverse events (AE) were hematologic, with grade 3 or severer leukopenia in 65% of patients, and 20% had grade 1 neutropenic fever. The research was funded by: This work was supported by grants from the National Natural Science Foundation of China (grant No. 81873450, 82170181), Beijing Hospitals Authority Youth Programme (code: QML20200201), and Beijing Natural Science Foundation (No.7222027) to Liang Wang. Keywords: Aggressive T-cell non-Hodgkin lymphoma, Chemotherapy, Combination Therapies No conflicts of interests pertinent to the abstract." @default.
- W4380085462 created "2023-06-10" @default.
- W4380085462 creator A5018655486 @default.
- W4380085462 creator A5024220393 @default.
- W4380085462 creator A5040027560 @default.
- W4380085462 creator A5074566396 @default.
- W4380085462 creator A5080947810 @default.
- W4380085462 date "2023-06-01" @default.
- W4380085462 modified "2023-10-12" @default.
- W4380085462 title "Combination of gemcitabine, pegaspargase, etoposide, and dexamethasone (GPED) in the treatment of advanced extranodal NK/T‐cell lymphoma" @default.
- W4380085462 doi "https://doi.org/10.1002/hon.3164_375" @default.
- W4380085462 hasPublicationYear "2023" @default.
- W4380085462 type Work @default.
- W4380085462 citedByCount "0" @default.
- W4380085462 crossrefType "journal-article" @default.
- W4380085462 hasAuthorship W4380085462A5018655486 @default.
- W4380085462 hasAuthorship W4380085462A5024220393 @default.
- W4380085462 hasAuthorship W4380085462A5040027560 @default.
- W4380085462 hasAuthorship W4380085462A5074566396 @default.
- W4380085462 hasAuthorship W4380085462A5080947810 @default.
- W4380085462 hasBestOaLocation W43800854621 @default.
- W4380085462 hasConcept C126322002 @default.
- W4380085462 hasConcept C141071460 @default.
- W4380085462 hasConcept C143998085 @default.
- W4380085462 hasConcept C2776694085 @default.
- W4380085462 hasConcept C2777063308 @default.
- W4380085462 hasConcept C2777589544 @default.
- W4380085462 hasConcept C2778119113 @default.
- W4380085462 hasConcept C2779338263 @default.
- W4380085462 hasConcept C2780258809 @default.
- W4380085462 hasConcept C2780401358 @default.
- W4380085462 hasConcept C2780873365 @default.
- W4380085462 hasConcept C2781413609 @default.
- W4380085462 hasConcept C71924100 @default.
- W4380085462 hasConcept C90924648 @default.
- W4380085462 hasConceptScore W4380085462C126322002 @default.
- W4380085462 hasConceptScore W4380085462C141071460 @default.
- W4380085462 hasConceptScore W4380085462C143998085 @default.
- W4380085462 hasConceptScore W4380085462C2776694085 @default.
- W4380085462 hasConceptScore W4380085462C2777063308 @default.
- W4380085462 hasConceptScore W4380085462C2777589544 @default.
- W4380085462 hasConceptScore W4380085462C2778119113 @default.
- W4380085462 hasConceptScore W4380085462C2779338263 @default.
- W4380085462 hasConceptScore W4380085462C2780258809 @default.
- W4380085462 hasConceptScore W4380085462C2780401358 @default.
- W4380085462 hasConceptScore W4380085462C2780873365 @default.
- W4380085462 hasConceptScore W4380085462C2781413609 @default.
- W4380085462 hasConceptScore W4380085462C71924100 @default.
- W4380085462 hasConceptScore W4380085462C90924648 @default.
- W4380085462 hasIssue "S2" @default.
- W4380085462 hasLocation W43800854621 @default.
- W4380085462 hasOpenAccess W4380085462 @default.
- W4380085462 hasPrimaryLocation W43800854621 @default.
- W4380085462 hasRelatedWork W15091867 @default.
- W4380085462 hasRelatedWork W1530620987 @default.
- W4380085462 hasRelatedWork W1982362071 @default.
- W4380085462 hasRelatedWork W202648080 @default.
- W4380085462 hasRelatedWork W2349181903 @default.
- W4380085462 hasRelatedWork W2430901395 @default.
- W4380085462 hasRelatedWork W2994693882 @default.
- W4380085462 hasRelatedWork W2997510975 @default.
- W4380085462 hasRelatedWork W764687 @default.
- W4380085462 hasRelatedWork W2242454958 @default.
- W4380085462 hasVolume "41" @default.
- W4380085462 isParatext "false" @default.
- W4380085462 isRetracted "false" @default.
- W4380085462 workType "article" @default.